CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 20 enrolled
Drug / intervention
MAXCLARITY II (2.5% BPO) Foam Cleanser +5 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02524665
NCT02524665Phase 4Completed
CompareCT.gov

U0289-404: An Evaluator Blinded, 8 Week, Split Face Study to Evaluate and Compare the Efficacy and Tolerability of MAXCLARITYII and MURAD in Subjects With Acne

Stiefel, a GSK Company·interventional·Posted Aug 17, 2015·Updated Apr 13, 2017

In Brief

A Phase 4 clinical trial evaluating MAXCLARITY II (2.5% BPO) Foam Cleanser, MAXCLARITY II (2.5% BPO) Foam Treatment, and 4 other interventions for Acne Vulgaris. Completed, enrolled 20 participants.

Detailed Summary

One of the main success factors in acne therapy is user compliance with treatment, product cost, availability and ease of use. Poor compliance may translate into decreased efficacy (either not improving symptoms well enough or not improving symptoms fast enough), tolerability issues or adverse effects (eg, erythema, dryness, or peeling of the skin), a lack of understanding of the instructions for use, or product cost/availability. Whatever the reason, poor compliance translates to decreased efficacy and increased frustration on the part of the user. The current study will evaluate and compare the efficacy and tolerability of 2 over the counter, topical product lines for the treatment of acne: MAXCLARITY II Foam Cleanser (2.5% benzoyl peroxide \[BPO\]) plus Foam Treatment (2.5% BPO) and (0.5% Salicylic Acid) Toner Foam compared with MURAD Clarifying Cleanser (1.5% salicylic acid \[SA\]) plus Exfoliating Acne Treatment Gel (1% SA) and Skin Perfecting Lotion.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcne Vulgaris
Countries--
Collaborators--

Timeline

Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedAug 17, 2015
Enrollment StartSep 1, 2009
Primary CompletionDec 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 10.9 years ago

Interventions

MAXCLARITY II (2.5% BPO) Foam Cleanserother

Available over the counter.

MAXCLARITY II (2.5% BPO) Foam Treatmentother

Available over the counter.

MAXCLARITY II (0.5% Salicylic Acid) Toner Foamother

Available over the counter.

MURAD Clarifying Cleanser (1.5% SA)other

Available over the counter.

Exfoliating Acne Treatment Gel (1% SA)other

Available over the counter.

Skin Perfecting Lotionother

Available over the counter.